Evidence map›Paper›PMID 23053340›Full record

ArticleDer Ophthalmologe : Zeitschrift der Deutschen Ophthalmologischen Gesellschaft2012

[Treatment of central serous chorioretinopathy: MicroPulse photocoagulation versus bevacizumab].

I Beger, M J Koss, F Koch

Abstract readControlled Clinical TrialEnglish Abstract
PubMed Publisher
In one paragraph

Article in Der Ophthalmologe : Zeitschrift der Deutschen Ophthalmologischen Gesellschaft, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed, 2 pooled it
0.8field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 2 syntheses or guidelines pooled it, 10 citations in OpenAlex.

  1. Interventions for central serous chorioretinopathy: a network meta-analysis.The Cochrane database of systematic reviews · 2025
    Pooled it
  2. Interventions for central serous chorioretinopathy: a network meta-analysis.The Cochrane database of systematic reviews · 2015
    Pooled it
  3. Long-term results and recurrence rates after spironolactone treatment in non-resolving central serous chorio-retinopathy (CSCR).Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie · 2017
    Trial
  4. Article
  5. Article
  6. Micropulse Laser Treatment of Retinal Diseases.Journal of clinical medicine · 2019
    Review
  7. [Treatment of serous macular retinal detachment with antihistamines].Der Ophthalmologe : Zeitschrift der Deutschen Ophthalmologischen Gesellschaft · 2015
    Review
  8. Spironolactone in the treatment of central serous chorioretinopathy - a case series.Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie · 2014
    Article
  9. Article
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

I BegerStudienzentrum Retina, Klinik für Glaskörper und Netzhautchirurgie, Zentrum der Augenheilkunde, Klinikum der Johann Wolfgang Goethe-Universität, Theodor Stern Kai 7 (Haus 7c), 60590, Frankfurt am Main, Deutschland. isbeger@stud.uni-frankfurt.de
M J Koss
F Koch
Goethe University Frankfurt · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeThe aim of this study was to evaluate the treatment of central serous chorioretinopathy (CSC) with either subthreshold diode-laser MicroPulse (MP) or intravitreal bevacizumab (BCZ) using the Pro Re Nata (PRN) scheme.

methodsThis comparative, controlled, prospective study over 10 months examined 52 eyes of 52 patients with either (a) treatment with MP at the active leakage site guided by fluorescein angiography (FA) (n=16 eyes), (b) intravitreal injection of 1.25 mg BCZ (n=10 eyes) or (c) passive observation (n=26 eyes). Outcome measures included changes in retinal pigment epithelium (RPE) leakage at FA, central macular thickness (CMT), best corrected visual acuity (BCVA) and 10° macular perimetry.

resultsAt the end of the study there was a 12.5 % persistent leakage in the MP group compared to 60 % in the BCZ group and 92 % in the control group. Mean CMT decreased by 94 µm in the MP, 38 µm in the BCZ and did not change in the control group. Mean BCVA improved by six ETDRS letters in the MP, decreased by one letter in the BCZ and by 2 letters in the control group. In the MP group mean perimetric deficit improved by 1.5 decibels and corrected lost variance by 2.6. In the BCZ it improved by 0.6 and by 0.5 in the control group. Retreatment was required in 7 out of 16 eyes of the SDM (43.75 %), and in 5 out of 10 eyes of the BCZ group (50 %).

conclusionsMP photocoagulation was superior to intravitreal injections of 1.25 mg BCZ in the treatment of CSC which resulted in enhanced visual acuity and macular perimetry.

Indexed as

Antibodies, Monoclonal, HumanizedBevacizumabCentral Serous ChorioretinopathyFemaleHumansLight CoagulationMaleMiddle AgedTreatment OutcomeVision DisordersAntibodies, Monoclonal, HumanizedBevacizumab

Identifiers

PMID23053340
OpenAlexW125943231

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.